124 related articles for article (PubMed ID: 37918263)
21. Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies.
Voutsadakis IA
Curr Oncol; 2022 Feb; 29(3):1390-1407. PubMed ID: 35323317
[No Abstract] [Full Text] [Related]
22. IL-27 mediates HLA class I up-regulation, which can be inhibited by the IL-6 pathway, in HLA-deficient Small Cell Lung Cancer cells.
Carbotti G; Nikpoor AR; Vacca P; Gangemi R; Giordano C; Campelli F; Ferrini S; Fabbi M
J Exp Clin Cancer Res; 2017 Oct; 36(1):140. PubMed ID: 29020964
[TBL] [Abstract][Full Text] [Related]
23. Tumor stemness score to estimate epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSCs) characterization and to predict the prognosis and immunotherapy response in bladder urothelial carcinoma.
Zhang Y; Zhang X; Huang X; Tang X; Zhang M; Li Z; Hu X; Zhang M; Wang X; Yan Y
Stem Cell Res Ther; 2023 Feb; 14(1):15. PubMed ID: 36721217
[TBL] [Abstract][Full Text] [Related]
24. Lack of association between HLA-E polymorphisms and transitional cell carcinoma of the bladder.
Veiga-Castelli LC; de Paula Cruz AS; Inácio MM; Mendes-Junior CT; Vianello-Brondani R; Moreau P; Castelli EC; Donadi EA
Tissue Antigens; 2013 Sep; 82(3):197-200. PubMed ID: 23786553
[No Abstract] [Full Text] [Related]
25. Identification of an immune-related long non-coding RNA signature and nomogram as prognostic target for muscle-invasive bladder cancer.
Song Y; Jin D; Chen J; Luo Z; Chen G; Yang Y; Liu X
Aging (Albany NY); 2020 Jun; 12(12):12051-12073. PubMed ID: 32579540
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of replication protein A3 is associated with unfavorable outcome in bladder urothelial carcinoma.
Sun D; Zhang K; Fu Q; Zhang H; Liu S; Wang H; Xu Z; Wang J
J Cancer Res Ther; 2021 Jul; 17(3):771-776. PubMed ID: 34269312
[TBL] [Abstract][Full Text] [Related]
27. Spatial Analysis and Clinical Significance of HLA Class-I and Class-II Subunit Expression in Non-Small Cell Lung Cancer.
Datar IJ; Hauc SC; Desai S; Gianino N; Henick B; Liu Y; Syrigos K; Rimm DL; Kavathas P; Ferrone S; Schalper KA
Clin Cancer Res; 2021 May; 27(10):2837-2847. PubMed ID: 33602682
[TBL] [Abstract][Full Text] [Related]
28. Prognostic DNA Methylation Biomarkers in High-risk Non-muscle-invasive Bladder Cancer: A Systematic Review to Identify Loci for Prospective Validation.
Gurung PMS; Barnett AR; Wilson JS; Hudson J; Ward DG; Messing EM; Bryan RT
Eur Urol Focus; 2020 Jul; 6(4):683-697. PubMed ID: 30803927
[TBL] [Abstract][Full Text] [Related]
29. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.
Negrao MV; Lam VK; Reuben A; Rubin ML; Landry LL; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Gibbons DL; Wistuba II; Papadimitrakopoulou V; Glisson BS; Blumenschein GR; Lee JJ; Heymach JV; Zhang J
J Thorac Oncol; 2019 Jun; 14(6):1021-1031. PubMed ID: 30780001
[TBL] [Abstract][Full Text] [Related]
30. ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy.
Klatte T; Seitz C; Rink M; Rouprêt M; Xylinas E; Karakiewicz P; Susani M; Shariat SF
J Urol; 2015 Nov; 194(5):1456-62. PubMed ID: 26162296
[TBL] [Abstract][Full Text] [Related]
31. TUBA1C is a potential new prognostic biomarker and promotes bladder urothelial carcinoma progression by regulating the cell cycle.
Jiang Y; Zhu C; Huang H; Huang G; Fu B; Xi X
BMC Cancer; 2023 Aug; 23(1):716. PubMed ID: 37528357
[TBL] [Abstract][Full Text] [Related]
32. Identification of prognostic and therapeutic value of CC chemokines in Urothelial bladder cancer: evidence from comprehensive bioinformatic analysis.
Li Y; Chen X; Li D; Yang Z; Bai Y; Hu S; Liu Z; Gu J; Zhang X
BMC Urol; 2021 Dec; 21(1):173. PubMed ID: 34893045
[TBL] [Abstract][Full Text] [Related]
33. Construction of Protein-related Risk Score Model in Bladder Urothelial Carcinoma.
Luo Q; Zhang X
Biomed Res Int; 2020; 2020():7147824. PubMed ID: 32802870
[TBL] [Abstract][Full Text] [Related]
34. Human Leukocyte Antigen Class I and Class II Polymorphisms and Serum Cytokine Profiles in Cervical Cancer.
Bahls L; Yamakawa R; Zanão K; Alfieri D; Flauzino T; Delongui F; de Abreu A; Souza R; Gimenes F; Reiche E; Borelli S; Consolaro M
Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28858203
[TBL] [Abstract][Full Text] [Related]
35. HLA-G expression in transitional bladder carcinoma. Relationship with tumor invasion level and patient survival: Experience in a public hospital in Argentina.
Moavro DE; Andrini L; Iribarne A; Colaci P; García M
Hum Immunol; 2023 Aug; 84(8):423-427. PubMed ID: 37069040
[TBL] [Abstract][Full Text] [Related]
36. Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer.
Guo CC; Dadhania V; Zhang L; Majewski T; Bondaruk J; Sykulski M; Wronowska W; Gambin A; Wang Y; Zhang S; Fuentes-Mattei E; Kamat AM; Dinney C; Siefker-Radtke A; Choi W; Baggerly KA; McConkey D; Weinstein JN; Czerniak B
Eur Urol; 2016 Oct; 70(4):611-620. PubMed ID: 26988609
[TBL] [Abstract][Full Text] [Related]
37. Predicting Prognosis and Distinguishing Cold and Hot Tumors in Bladder Urothelial Carcinoma Based on Necroptosis-Associated lncRNAs.
Liu D; Xu S; Chang T; Ma S; Wang K; Sun G; Chen S; Xu Y; Zhang H
Front Immunol; 2022; 13():916800. PubMed ID: 35860239
[TBL] [Abstract][Full Text] [Related]
38. IMP3 is a biomarker for non-muscle-invasive urothelial carcinoma of the bladder associated with an aggressive phenotype.
Yang F; Zhou Q; Meng L; Xing N
Medicine (Baltimore); 2019 Jul; 98(27):e16009. PubMed ID: 31277094
[TBL] [Abstract][Full Text] [Related]
39. TRBV and TRBJ usage, when paired with specific HLA alleles, associates with distinct head and neck cancer survival rates.
Arndt MF; Koohestani DM; Chobrutskiy BI; Mihyu MM; Diaz M; Gozlan EC; Yeagley M; Zaman S; Roca AM; Blanck G
Hum Immunol; 2020 Dec; 81(12):692-696. PubMed ID: 32950267
[TBL] [Abstract][Full Text] [Related]
40. T cell receptor-β J usage, in combination with particular HLA class II alleles, correlates with better cancer survival rates.
Callahan BM; Tong WL; Blanck G
Immunol Res; 2018 Apr; 66(2):219-223. PubMed ID: 29594966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
